Welcome to the OMA Blog

Article Summary Treatment Across the Care Continuum in Adolescent Obesity Management: This article reviews the complexity of treating adolescents affected by obesity using antiobesity medications and metabolic bariatric surgery, the potential role of concurrent versus singular treatment strategies and highlights and the need for further research to define optimal timing of these therapies in the adolescent population. Read the Full Article Article Review The treatment landscape for adolescents affected by obesity in the United States has changed dramatically over the past few years. This article highlights the growing impact of adolescent obesity, current information, epidemiology, unique features of adolescent obesity, barriers to care and reviews current treatment options, including antiobesity pharmacotherapy and metabolic bariatric surgery (MBS). Expanding pediatric obesity programs that offer comprehensive care, including lifestyle interventions, anti-obesity medications, and adolescent MBS may help optimize treatment strategies and improve long-term outcomes for adolescents with obesity. Reframing obesity treatment in the adolescent population using a chronic disease model would shift the perspective from viewing treatment as a one-time intervention to recognizing it as part of a continuous, long-term care process. Adopting this model may improve the sustainability of weight management, support the prevention and treatment of weight regain, and promote better long-term health outcomes for adolescents living with obesity. Implications for adult and pediatric obesity specialists include advocating for patients access to evidence-based care, including treatment for adolescents affected by obesity and its associated comorbidities.

New “Treating Obesity First” initiative introduces OMAr, an interactive training tool designed to help clinicians practice real-world patient discussions

Discover the most effective weight loss medications approved by the FDA. Comprehensive guide on safety, dosage, and efficacy for 2025.

Weight loss medications have undergone a sea change in the past several years. With the rise of incretin therapies, two names have emerged as leaders: tirzepatide and semaglutide. They share many similarities. The frequency with which we hear these two drug names bandied about, along with their brand names — Mounjaro/Zepbound and Ozempic/Wegovy, respectively — can lead to confusion.

Learn how a low carb diet supports obesity treatment. Explore carbohydrate definitions, sex-specific metabolic effects, and clinical risks.

Explore the clinical impact of weight cycling. This guide for healthcare providers covers the risks, physiological mechanisms, and patient communication strategies.

Learn about metabolic flexibility and its role in obesity treatment in this in-depth guide for healthcare providers.

Obesity is no longer a looming public health threat—it is a full-scale epidemic. More than 40% of U.S. adults live with obesity,1 driving increased risk of type 2 diabetes, cardiovascular-kidney metabolic disease, and reduced quality of life and life expectancy.

By the age of 10, Murielle Véniant knew she had a passion for biology. Originally focused on a future as a veterinarian, she shifted her attention to humans in her teenage years after her uncle unexpectedly passed away from a heart attack at 49.